JP2014505660A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505660A5 JP2014505660A5 JP2013539220A JP2013539220A JP2014505660A5 JP 2014505660 A5 JP2014505660 A5 JP 2014505660A5 JP 2013539220 A JP2013539220 A JP 2013539220A JP 2013539220 A JP2013539220 A JP 2013539220A JP 2014505660 A5 JP2014505660 A5 JP 2014505660A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- hydroxy
- alkoxy
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41417410P | 2010-11-16 | 2010-11-16 | |
| US61/414,174 | 2010-11-16 | ||
| PCT/EP2011/070084 WO2012065958A1 (en) | 2010-11-16 | 2011-11-14 | Method of treating contrast-induced nephropathy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014505660A JP2014505660A (ja) | 2014-03-06 |
| JP2014505660A5 true JP2014505660A5 (enExample) | 2015-01-08 |
| JP5950926B2 JP5950926B2 (ja) | 2016-07-13 |
Family
ID=44993552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539220A Expired - Fee Related JP5950926B2 (ja) | 2010-11-16 | 2011-11-14 | 造影剤誘発性腎症の処置方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8993631B2 (enExample) |
| EP (1) | EP2640375B1 (enExample) |
| JP (1) | JP5950926B2 (enExample) |
| KR (1) | KR101886894B1 (enExample) |
| CN (2) | CN104306974B (enExample) |
| AU (1) | AU2011331296C1 (enExample) |
| BR (1) | BR112013011876A2 (enExample) |
| CA (1) | CA2817784C (enExample) |
| CL (1) | CL2013001383A1 (enExample) |
| EA (1) | EA029672B1 (enExample) |
| ES (1) | ES2587447T3 (enExample) |
| IL (1) | IL226351A (enExample) |
| MA (1) | MA35085B1 (enExample) |
| MX (1) | MX2013005543A (enExample) |
| PH (1) | PH12013500993A1 (enExample) |
| PL (1) | PL2640375T3 (enExample) |
| PT (1) | PT2640375T (enExample) |
| SG (1) | SG190229A1 (enExample) |
| TW (1) | TWI576331B (enExample) |
| WO (1) | WO2012065958A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013016595B1 (pt) | 2010-12-15 | 2021-04-27 | Theravance Biopharma R&D Ip, Llc | Composto inibidor de neprilisina, processos para a preparação e intermediários do referido composto, composição farmacêutica e uso do composto |
| ES2548887T3 (es) | 2010-12-15 | 2015-10-21 | Theravance Biopharma R&D Ip, Llc | Inhibidores de neprilisina |
| US8449890B2 (en) | 2011-02-17 | 2013-05-28 | Theravance, Inc. | Neprilysin inhibitors |
| RU2604522C2 (ru) | 2011-02-17 | 2016-12-10 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи,ЭлЭлСи | Замещенные аминомасляные производные в качестве ингибиторов неприлизина |
| EP2714660B1 (en) | 2011-05-31 | 2018-09-26 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
| US8686184B2 (en) | 2011-05-31 | 2014-04-01 | Theravance, Inc. | Neprilysin inhibitors |
| WO2012166387A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
| TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| CA2871292A1 (en) * | 2012-05-31 | 2013-12-05 | Theravance Biopharma R&D Ip, Llc | Nitric oxide donor neprilysin inhibitors |
| US8871792B2 (en) | 2012-06-08 | 2014-10-28 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
| EP2864292B1 (en) | 2012-06-08 | 2017-04-12 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
| PL2882716T3 (pl) | 2012-08-08 | 2017-06-30 | Theravance Biopharma R&D Ip, Llc | Inhibitory neprylizyny |
| MX2015010434A (es) * | 2013-02-14 | 2015-10-05 | Novartis Ag | Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo. |
| HRP20180958T1 (hr) * | 2013-02-14 | 2018-07-27 | Novartis Ag | Supstituirani derivati bisfenolbutanfosfonske kiseline kao inhibitori za nep (neutralnu endopeptidazu) |
| HRP20171097T1 (hr) * | 2013-03-05 | 2017-10-06 | Theravance Biopharma R&D Ip, Llc | Inhibitori neprilizina |
| KR20160113291A (ko) | 2014-01-30 | 2016-09-28 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 네프리리신 저해제 |
| AU2015211041B2 (en) | 2014-01-30 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors |
| WO2016037098A1 (en) * | 2014-09-04 | 2016-03-10 | Concert Pharmaceuticals, Inc. | Deuterated sacubitril |
| CN104557600B (zh) * | 2015-01-26 | 2016-05-04 | 苏州明锐医药科技有限公司 | 沙库比曲的制备方法 |
| JP6766055B2 (ja) | 2015-02-11 | 2020-10-07 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ネプリライシン阻害剤としての（２ｓ，４ｒ）−５−（５’−クロロ−２’−フルオロビフェニル−４−イル）−４−（エトキシオキサリルアミノ）−２−ヒドロキシメチル−２−メチルペンタン酸 |
| LT3259255T (lt) | 2015-02-19 | 2021-04-26 | Theravance Biopharma R&D Ip, Llc | (2r,4r)-5-(5`-chlor-2`-fluorbifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentano rūgštis |
| MX2017012110A (es) * | 2015-03-20 | 2018-02-19 | Crystal Pharmatech Co Ltd | Forma cristalina de ahu377, metodo de preparacion y uso de la misma. |
| CN105061263B (zh) * | 2015-08-11 | 2017-03-15 | 苏州楚凯药业有限公司 | 一种nep抑制剂中间体的制备方法 |
| CN105523964B (zh) * | 2015-12-09 | 2017-05-24 | 苏州楚凯药业有限公司 | 一种抗心衰药物中间体的制备方法 |
| RU2756223C2 (ru) | 2016-03-08 | 2021-09-28 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Кристаллическая (2s,4r)-5-(5'-хлор-2'-фтор-[1,1'-бифенил]-4-ил)-2-(этоксиметил)-4-(3-гидроксиизоксазол-5-карбоксамидо)-2-метилпентановая кислота и ее применения |
| WO2017152755A1 (zh) * | 2016-03-10 | 2017-09-14 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的联苯基化合物及其药物组合物 |
| CN105963569A (zh) * | 2016-06-25 | 2016-09-28 | 许风英 | 一种预防缓解碘造影剂副作用的中药制剂 |
| CN107602399B (zh) * | 2016-07-11 | 2020-09-25 | 江西东邦药业有限公司 | 一种脑啡肽酶抑制剂中间体的制备方法 |
| CN107382785B (zh) * | 2017-08-09 | 2019-11-01 | 常州制药厂有限公司 | 一种沙库必曲关键中间体的制备方法 |
| FR3072379B1 (fr) * | 2017-10-18 | 2020-08-07 | Pharmasynthese | Nouveaux derives de la strombine et leur utilisation en cosmetique |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| US12168643B2 (en) | 2019-06-19 | 2024-12-17 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| CN110711544A (zh) * | 2019-10-12 | 2020-01-21 | 浙江理工大学上虞工业技术研究院有限公司 | 一种自粘性芳香微胶囊的制备方法 |
| KR102308991B1 (ko) | 2020-04-08 | 2021-10-06 | 압타바이오 주식회사 | 조영제 유발 급성 신부전 치료제 |
| EP4134079A4 (en) | 2020-04-08 | 2024-04-24 | Aptabio Therapeutics Inc. | AGENT FOR THE TREATMENT OF ACUTE KIDNEY INJURY INDUCED BY CONTRAST PRODUCT |
| KR102504090B1 (ko) | 2020-08-05 | 2023-02-24 | 경상국립대학교병원 | 조영제-유발 신독성 예방 또는 치료용 약학 조성물 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB447841A (en) | 1933-12-23 | 1936-05-27 | Anton Tolk | Improvements in and relating to compression refrigerating machines |
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US4610816A (en) | 1980-12-18 | 1986-09-09 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
| US4640816A (en) | 1984-08-31 | 1987-02-03 | California Institute Of Technology | Metastable alloy materials produced by solid state reaction of compacted, mechanically deformed mixtures |
| US4929641B1 (en) | 1988-05-11 | 1994-08-30 | Schering Corp | Mercapto-acylamino acid antihypertensives |
| EP0254032A3 (en) * | 1986-06-20 | 1990-09-05 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| FR2623498B1 (fr) | 1987-11-24 | 1990-04-06 | Bioprojet Soc Civ | Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques |
| GB8811873D0 (en) | 1988-05-19 | 1988-06-22 | Pfizer Ltd | Therapeutic agents |
| GB8820844D0 (en) | 1988-09-05 | 1988-10-05 | Pfizer Ltd | Therapeutic agents |
| US5599951A (en) | 1989-09-15 | 1997-02-04 | Societe Civile Bioprojet | Amino acid derivatives, the process for their preparation and their applications to therapy |
| FR2652087B1 (fr) * | 1989-09-15 | 1993-10-15 | Bioprojet Ste Civile | Derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques. |
| FR2673105B1 (fr) * | 1991-02-26 | 1995-01-13 | Bioprojet Soc Civ | Nouvelles compositions pharmaceutiques, notamment pour le traitement des colopathies fonctionnelles, et procedes de preparation de compositions et de medicaments, notamment pour le traitement de ces affections. |
| US5155100A (en) | 1991-05-01 | 1992-10-13 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipeptide derivatives |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| US5514696A (en) | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
| RU2124503C1 (ru) | 1992-05-18 | 1999-01-10 | И.Р.Сквибб энд Санз, Инк. | Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция |
| US5508272A (en) * | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5780473A (en) | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| DE19510566A1 (de) | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US5846985A (en) | 1997-03-05 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| US6660756B2 (en) | 2001-03-28 | 2003-12-09 | Pfizer Inc. | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| MXPA03006597A (es) | 2001-03-28 | 2004-10-15 | Pfizer | Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad. |
| PL209338B1 (pl) | 2001-04-12 | 2011-08-31 | Sanofi Aventis Deutschland | Pochodne merkaptoacetyloamidu, ich zastosowanie oraz kompozycja farmaceutyczna zawierająca te pochodne |
| WO2002083130A1 (en) | 2001-04-16 | 2002-10-24 | Bristol-Myers Squibb Company | Enantiomers of n-[[2'-[[(4,5-dimethyl-3-isoxazolyl) amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-n,3,3-trimethylbutanamide |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2003232941A1 (en) | 2002-06-07 | 2003-12-22 | Glaxo Group Limited | N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them |
| WO2005009973A1 (en) | 2003-06-26 | 2005-02-03 | Novartis Ag | 5-membered heterocycle-based p38 kinase inhibitors |
| WO2005040345A2 (en) | 2003-09-24 | 2005-05-06 | Vertex Pharmceuticals Incorporated | 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase |
| US20050267072A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction |
| WO2006015885A1 (en) | 2004-08-13 | 2006-02-16 | University College Dublin, National University Of Ireland, Dublin | Amino acid dehydrogenase-derived biocatalysts |
| US20060205625A1 (en) | 2005-02-18 | 2006-09-14 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
| ATE464904T1 (de) | 2005-02-18 | 2010-05-15 | Solvay Pharm Gmbh | Pharmazeutische zusammensetzungen mit nep- inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika |
| PL1940818T3 (pl) | 2005-10-25 | 2012-01-31 | Pharmaleads | Pochodne aminokwasów zawierające grupę disulfanylową jako mieszane inhibitory neprylizyny i aminopeptydazy n |
| WO2007109456A2 (en) | 2006-03-16 | 2007-09-27 | Pharmacopeia, Inc. | Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists |
| EP1903027A1 (en) | 2006-09-13 | 2008-03-26 | Novartis AG | Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors |
| CN101631765B (zh) | 2007-01-12 | 2014-10-01 | 诺华股份有限公司 | 用于制备5-联苯基-4-氨基-2-甲基戊酸的方法 |
| TW200838501A (en) * | 2007-02-02 | 2008-10-01 | Theravance Inc | Dual-acting antihypertensive agents |
| TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| EP2200975A1 (en) | 2007-09-07 | 2010-06-30 | Theravance, Inc. | Dual-acting antihypertensive agents |
| JP2011518884A (ja) | 2008-04-29 | 2011-06-30 | セラヴァンス， インコーポレーテッド | 二重活性抗高血圧剤 |
| EP2594557B1 (en) | 2009-05-28 | 2016-08-10 | Novartis AG | Substituted aminopropionic derivatives as neprilysin inhibitors |
| SG176010A1 (en) | 2009-05-28 | 2011-12-29 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
-
2011
- 2011-11-11 US US13/294,295 patent/US8993631B2/en not_active Expired - Fee Related
- 2011-11-14 CA CA2817784A patent/CA2817784C/en not_active Expired - Fee Related
- 2011-11-14 CN CN201410468788.9A patent/CN104306974B/zh not_active Expired - Fee Related
- 2011-11-14 PH PH1/2013/500993A patent/PH12013500993A1/en unknown
- 2011-11-14 KR KR1020137015363A patent/KR101886894B1/ko not_active Expired - Fee Related
- 2011-11-14 SG SG2013035886A patent/SG190229A1/en unknown
- 2011-11-14 BR BR112013011876A patent/BR112013011876A2/pt not_active Application Discontinuation
- 2011-11-14 JP JP2013539220A patent/JP5950926B2/ja not_active Expired - Fee Related
- 2011-11-14 WO PCT/EP2011/070084 patent/WO2012065958A1/en not_active Ceased
- 2011-11-14 MX MX2013005543A patent/MX2013005543A/es not_active Application Discontinuation
- 2011-11-14 CN CN201180065284.7A patent/CN103313708B/zh not_active Expired - Fee Related
- 2011-11-14 EA EA201390707A patent/EA029672B1/ru not_active IP Right Cessation
- 2011-11-14 EP EP11784638.6A patent/EP2640375B1/en not_active Not-in-force
- 2011-11-14 PL PL11784638T patent/PL2640375T3/pl unknown
- 2011-11-14 PT PT117846386T patent/PT2640375T/pt unknown
- 2011-11-14 AU AU2011331296A patent/AU2011331296C1/en not_active Ceased
- 2011-11-14 ES ES11784638.6T patent/ES2587447T3/es active Active
- 2011-11-15 TW TW100141713A patent/TWI576331B/zh not_active IP Right Cessation
-
2013
- 2013-05-13 IL IL226351A patent/IL226351A/en active IP Right Grant
- 2013-05-15 CL CL2013001383A patent/CL2013001383A1/es unknown
- 2013-06-05 MA MA35961A patent/MA35085B1/fr unknown
-
2014
- 2014-07-28 US US14/341,977 patent/US20140336194A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014505660A5 (enExample) | ||
| PE20241127A1 (es) | Compuestos triciclicos como inhibidores de kras | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| BR112013025634A2 (pt) | inibidores de hsp90 | |
| AU2018226470A1 (en) | Compounds for treatment of cancer | |
| JP2015518004A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| EA200970535A1 (ru) | Антибактериальные производные хинолина | |
| CR20200418A (es) | Inhibidores de orginasa y sus mètodos de uso antecedentes | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| RU2010126056A (ru) | Органические соединения | |
| JP2011521938A5 (enExample) | ||
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| RU2018114518A (ru) | Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca) | |
| JP2011516498A5 (enExample) | ||
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| JP2013522368A5 (enExample) | ||
| RU2012110380A (ru) | Новое производное 5-фторурацила | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| RU2013136895A (ru) | Новое бициклическое соединение или его соль | |
| RU2007118727A (ru) | Ингибиторы mif | |
| RU2013136861A (ru) | Новое производное индола или индазола или его соль | |
| RU2009128970A (ru) | Производные изосорбидмононитрата для лечения кишечных заболеваний | |
| RU2014112320A (ru) | Ингибитор pi3k, предназначенный для применения для лечения рака кости или для предупреждения метастатической диссеминации первичных раковых клеток в кость | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. |